GnRHa is the standard treatment for central precocious puberty; GnRHa slows down the patient’s excessive growth rate and skeletal maturation, increasing the patient’s height in adulthood. However, in some patients, the growth rate is so severely slowed that it does not lead to an increase in final height. Oxandrolone is an anabolic androgen whose growth-promoting effects counteract the excessive growth-slowing effect of GnRHa. Ghizzoni et al. in Italy evaluated the final height of 20 girls with precocious puberty, whose growth was significantly slowed during GnRHa treatment; 10 girls were treated with oxandrolone and 10 girls were not. The results showed that the mean adult height of the girls in the oxandrolone group was 162.2 cm, whereas the adult height of the girls who continued with GnRHa alone (151.9 cm) was similar to the predicted height before treatment and significantly lower than their target height (156.6 cm, P<0.005). There were no adverse effects in either group. The investigators concluded that the combination of GnRHa and oxandrolone may reduce the growth slowdown during GnRHa treatment in children with central precocious puberty and increase their height in adulthood, which is a practical treatment option.